

Guadalupe Gomez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9217497/publications.pdf>

Version: 2024-02-01

78
papers

2,072
citations

304602

22
h-index

254106

43
g-index

85
all docs

85
docs citations

85
times ranked

3102
citing authors

#	ARTICLE	IF	CITATIONS
1	A class of two-sample nonparametric statistics for binary and time-to-event outcomes. <i>Statistical Methods in Medical Research</i> , 2022, 31, 225-239.	0.7	0
2	Description of survival with numerical and graphic indicators. Basics and mistakes to avoid. <i>Cirug�a Espa�ola (English Edition)</i> , 2022, 100, 587-589.	0.1	0
3	Analyzing left-truncated and right-censored infectious disease cohort data with interval-censored infection onset. <i>Statistics in Medicine</i> , 2021, 40, 287-298.	0.8	2
4	Using the geometric average hazard ratio in sample size calculation for time-to-event data with composite endpoints. <i>BMC Medical Research Methodology</i> , 2021, 21, 99.	1.4	1
5	Design of phase III trials with long-term survival outcomes based on short-term binary results. <i>Statistics in Medicine</i> , 2021, 40, 4122-4135.	0.8	0
6	Selection of nature-based solutions to improve comfort in schools during heat waves. <i>International Journal of Energy Production and Management</i> , 2021, 6, 157-169.	1.9	7
7	A nonparametric test for the association between longitudinal covariates and censored survival data. <i>Biostatistics</i> , 2020, 21, 727-742.	0.9	1
8	Modeling the Coronavirus Disease 2019 Incubation Period: Impact on Quarantine Policy. <i>Mathematics</i> , 2020, 8, 1631.	1.1	10
9	Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction. <i>European Journal of Cancer</i> , 2020, 132, 53-60.	1.3	16
10	HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02). <i>Frontiers in Immunology</i> , 2020, 11, 823.	2.2	55
11	Multiple imputation approach for interval-censored time to HIV RNA viral rebound within a mixed effects Cox model. <i>Biometrical Journal</i> , 2019, 61, 299-318.	0.6	4
12	Using the STROBE statement: survey findings emphasized the role of journals in enforcing reporting guidelines. <i>Journal of Clinical Epidemiology</i> , 2019, 116, 26-35.	2.4	36
13	Advanced Topics in Biostatistics: Editorial for the ISCB38 Special Issue. <i>Biometrical Journal</i> , 2019, 61, 243-244.	0.6	0
14	A cross-sectional bibliometric study showed suboptimal journal endorsement rates of STROBE and its extensions. <i>Journal of Clinical Epidemiology</i> , 2019, 107, 42-50.	2.4	31
15	A new approach for sizing trials with composite binary endpoints using anticipated marginal values and accounting for the correlation between components. <i>Statistics in Medicine</i> , 2019, 38, 1935-1956.	0.8	3
16	Survival analysis model to estimate sensory shelf life with temperature and illumination as accelerating factors. <i>Food Quality and Preference</i> , 2018, 68, 371-376.	2.3	12
17	Selection of composite binary endpoints in clinical trials. <i>Biometrical Journal</i> , 2018, 60, 246-261.	0.6	7
18	High risk and probability of progression to osteoporosis at 10 years in HIV-infected individuals: the role of PIs. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2452-2459.	1.3	6

#	ARTICLE	IF	CITATIONS
19	The Use of a Binary Composite Endpoint and Sample Size Requirement: Influence of Endpoints Overlap. American Journal of Epidemiology, 2017, 185, 832-841.	1.6	7
20	Identification of Interleukin-27 (IL-27)/IL-27 Receptor Subunit Alpha as a Critical Immune Axis for <i>In Vivo</i> HIV Control. Journal of Virology, 2017, 91, .	1.5	18
21	The STROBE extensions: protocol for a qualitative assessment of content and a survey of endorsement. BMJ Open, 2017, 7, e019043.	0.8	12
22	A Multi-state Model for the Progression to Osteopenia and Osteoporosis Among HIV-Infected Patients. Trends in Mathematics, 2017, , 41-45.	0.1	0
23	An Ordinal Joint Model for Breast Cancer. Trends in Mathematics, 2017, , 9-13.	0.1	0
24	Comments on "Use of composite endpoints in clinical trials" by Abdul J. Sankoh, Haihong Li and Ralph B. D'Agostino, Sr. Statistics in Medicine, 2016, 35, 317-318.	0.8	1
25	Selection of the primary end point in an observational cohort study. Journal of Epidemiology and Community Health, 2016, 70, 950-953.	2.0	2
26	Bayesian joint ordinal and survival modeling for breast cancer risk assessment. Statistics in Medicine, 2016, 35, 5267-5282.	0.8	20
27	Selecting the primary endpoint in a randomized clinical trial: The ARE method. Journal of Biopharmaceutical Statistics, 2016, 26, 880-898.	0.4	1
28	FARMS: A New Algorithm for Variable Selection. BioMed Research International, 2015, 2015, 1-11.	0.9	2
29	Sensory cut-off point obtained from survival analysis statistics. Food Quality and Preference, 2015, 43, 135-140.	2.3	15
30	Frequentist and Bayesian approaches for a joint model for prostate cancer risk and longitudinal prostate-specific antigen data. Journal of Applied Statistics, 2015, 42, 1223-1239.	0.6	11
31	Prenatal Exposure to Maternal Bereavement and Childbirths in the Offspring: A Population-Based Cohort Study. PLoS ONE, 2014, 9, e103353.	1.1	4
32	Correcting the bias due to dependent censoring of the survival estimator by conditioning. Statistics, 2014, 48, 295-314.	0.3	0
33	Informed Choice of Composite End Points in Cardiovascular Trials. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 170-178.	0.9	21
34	Estimation and residual analysis with R for a linear regression model with an interval-censored covariate. Biometrical Journal, 2014, 56, 867-885.	0.6	9
35	Statistical considerations when using a composite endpoint for comparing treatment groups. Statistics in Medicine, 2013, 32, 719-738.	0.8	30
36	A dynamic model for the risk of bladder cancer progression. Statistics in Medicine, 2012, 31, 287-300.	0.8	7

#	ARTICLE	IF	CITATIONS
37	A generalized Fleming and Harrington's class of tests for interval-censored data. <i>Canadian Journal of Statistics</i> , 2012, 40, 501-516.	0.6	11
38	Time of Progression to Osteopenia/Osteoporosis in Chronically HIV-Infected Patients: Screening DXA Scan. <i>PLoS ONE</i> , 2012, 7, e46031.	1.1	16
39	Volcanic hazard assessment for the Canary Islands (Spain) using extreme value theory. <i>Natural Hazards and Earth System Sciences</i> , 2011, 11, 2741-2753.	1.5	34
40	Definition of the viral targets of protective HIV-1-specific T cell responses. <i>Journal of Translational Medicine</i> , 2011, 9, 208.	1.8	143
41	Simultaneous marginal survival estimators when doubly censored data is present. <i>Lifetime Data Analysis</i> , 2011, 17, 347-372.	0.4	3
42	Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?. <i>Journal of NeuroVirology</i> , 2010, 16, 208-218.	1.0	13
43	High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. <i>Aids</i> , 2010, 24, 2827-2833.	1.0	140
44	Tutorial on methods for interval-censored data and their implementation in R. <i>Statistical Modelling</i> , 2009, 9, 259-297.	0.5	96
45	Nadir CD4 Cell Count Predicts Neurocognitive Impairment in HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 1301-1307.	0.5	87
46	Sustained antiretroviral treatment adherence in survivors of the pre-HAART era: attitudes and beliefs. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2008, 20, 796-805.	0.6	31
47	A Sampling-Based Chi-Squared Test for Interval-Censored Data. , 2008, , 295-306.		3
48	Interval censoring: identifiability and the constant-sum property. <i>Biometrika</i> , 2007, 94, 61-70.	1.3	15
49	Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfecting patients. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2007, 19, 138-145.	0.6	46
50	Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. <i>Aids</i> , 2007, 21, 169-178.	1.0	74
51	Bayesian survival analysis modeling applied to sensory shelf life of foods. <i>Food Quality and Preference</i> , 2006, 17, 307-312.	2.3	26
52	Sensory shelf-life predictions by survival analysis accelerated storage models. <i>Food Quality and Preference</i> , 2006, 17, 468-473.	2.3	65
53	Estimating the Shelf Life of Brown Pan Bread, Suitability of Survival Analysis Methodology. <i>Journal of Food Science</i> , 2006, 71, S321-S325.	1.5	8
54	Long-Term Neuropsychiatric Disorders on Efavirenz-Based Approaches. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 38, 560-565.	0.9	151

#	ARTICLE	IF	CITATIONS
55	A SEMIPARAMETRIC HIERARCHICAL METHOD FOR A REGRESSION MODEL WITH AN INTERVAL-CENSORED COVARIATE. Australian and New Zealand Journal of Statistics, 2005, 47, 351-364.	0.4	5
56	Likelihood Maximization Using Web-Based Optimization Tools. American Statistician, 2005, 59, 192-202.	0.9	5
57	Baseline Factors associated with Haematological Toxicity that Leads to a Dosage Reduction of Pegylated Interferon- α 2a and Ribavirin in HIV- and HCV-Coinfected Patients on HCV Antiviral Therapy. Antiviral Therapy, 2005, 10, 841-847.	0.6	15
58	Interval censoring: Model characterizations for the validity of the simplified likelihood. Canadian Journal of Statistics, 2004, 32, 315-326.	0.6	41
59	Frequentist and Bayesian approaches for interval-censored data. Statistical Papers, 2004, 45, 139-173.	0.7	41
60	Residual analysis in linear regression models with an interval-censored covariate. Statistics in Medicine, 2004, 23, 3377-3391.	0.8	19
61	A parametric survival model with an interval-censored covariate. Statistics in Medicine, 2004, 23, 3159-3175.	0.8	17
62	Inference for a linear regression model with an interval-censored covariate. Statistics in Medicine, 2003, 22, 409-425.	0.8	44
63	Survival Analysis Applied to Sensory Shelf Life of Foods. Journal of Food Science, 2003, 68, 359-362.	1.5	168
64	Nonparametric Bayesian estimation from interval-censored data using Monte Carlo methods. Journal of Statistical Planning and Inference, 2001, 98, 73-87.	0.4	14
65	Risk of HIV infection as a function of the duration of intravenous drug use: a non-parametric Bayesian approach. Statistics in Medicine, 2000, 19, 2641-2656.	0.8	12
66	Non-parametric estimation with doubly censored data. Journal of Applied Statistics, 1999, 26, 45-58.	0.6	23
67	Supervivencia en pacientes con tuberculosis infectados por VIH. Estudio de los fallecimientos en los primeros nueve meses. Revista Espanola De Salud Publica, 1999, 73, 549-562.	0.3	3
68	Left-truncated Data With Age as Time Scale: An Alternative for Survival Analysis in the Elderly Population. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 1998, 53A, M337-M343.	1.7	179
69	CD4+ lymphocytes and tuberculin skin test as survival predictors in pulmonary tuberculosis HIV-infected patients. International Journal of Epidemiology, 1998, 27, 703-712.	0.9	5
70	Decreased survival of patients with lung cancer admitted to a teaching hospital through the emergency department in Barcelona, Spain. Journal of Epidemiology and Community Health, 1998, 52, 137-138.	2.0	5
71	Asymptotic properties of the left kaplan-meier estimator. Communications in Statistics - Theory and Methods, 1994, 23, 123-135.	0.6	4
72	Cancer survival and the duration of symptoms. An analysis of possible forms of the risk function. European Journal of Cancer, 1994, 30, 785-792.	1.3	56

#	ARTICLE	IF	CITATIONS
73	Estimation of the Infection Time and Latency Distribution of AIDS with Doubly Censored Data. Biometrics, 1994, 50, 204.	0.8	50
74	Estimation of the infection time and latency distribution of AIDS with doubly censored data. Biometrics, 1994, 50, 204-12.	0.8	12
75	Estimation of the subsurvival function for time-to-tumor in survival/sacrifice experiments. Statistics and Probability Letters, 1992, 13, 5-13.	0.4	3
76	Survival Analysis For Left Censored Data. , 1992, , 269-288.		10
77	Estimation and Asymptotic Properties of the Distribution of Tune-to-Tumour in Carcinogenesis Experiments. Mathematical Medicine and Biology, 1990, 7, 109-123.	0.8	3
78	A Homogeneity Test for Follow-up Studies. Mathematical Medicine and Biology, 1988, 5, 101-112.	0.8	1